Advertisement

Non-Hodgkin-Lymphome bei Kindern und Jugendlichen

  • Guido Seitz
  • Christine Mauz-Körholz
Living reference work entry
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Die Non-Hodgkin-Lymphome (NHL) stellen eine heterogene Gruppe von bösartigen Erkrankungen des lymphatischen Systems dar und umfassen alle bösartigen Lymphome, die keine Hodgkin-Lymphome sind. Sie sind im Kindes- und Jugendalter hoch aggressiv und schnell wachsend. Die relative Häufigkeit in Deutschland beträgt 6,2 % aller Tumorerkrankungen im Kindesalter. Typische Vertreter sind die Burkitt-Lymphome inkl. der reifzelligen B-Zelltyp-Leukämien, die T- und B-lymphoblastischen Lymphome sowie die großzellig anaplastischen Lymphome. Die klinische Symptomatik ist heterogen und reicht von der schmerzlosen Lymphadenopathie, über das akute Abdomen, pulmonale Symptome bei mediastinalem Tumorbefall, ZNS-Symptome bis hin zur Zytopenie bei Knochenmarkbeteiligung. Die Diagnosesicherung erfolgt histologisch. Die Behandlung erfolgt mittels Zytostatika. Die chirurgische Therapie ist abdominellen Notfallsituationen vorbehalten. Die Prognose ist insgesamt gut.

Literatur

  1. Abbasoglu L, Gün F, Salman FT, Celik A, Unüvar A, Görgün O (2003) The role of surgery in intraabdominal Burkitt’s lymphoma in children. Eur J Pediatr Surg 13(4):236–239CrossRefPubMedGoogle Scholar
  2. Acker SN, Linton J, Tam GM, Garrington TP, Bruny J, Hilden JM, Hoffman LM, Partrick DA (2015) A multidisciplinary approach to the management of anterior mediastinal masses in children. J Pediatr Surg 50(5):875–878CrossRefPubMedGoogle Scholar
  3. Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, Bubanska E, Burkhardt B, Chiang AKS, Csoka M, Fedorava A, Jazbec J, Kabickova E, Krenova Z, Lazic J, Loeffen J, Mann G, Niggli F, Miakova N, Osumi T, Ronceray L, Uyttebroeck A, Williams D, Woessmann W, Wrobel G, Pillon M, on behalf of the European Intergroup for Childhood Non-Hodgkin-Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group (2016) Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica 101(12):1581–1591Google Scholar
  4. Betsch B, Brado M, Wunsch C, Richter GM, Kauffmann GW, Tröger J (1997) Malignant lymphoma in childhood. Ultrasound diagnosis. Radiologe 37(1):62–73CrossRefPubMedGoogle Scholar
  5. Brugieres L, Le Deley MC, Paquement H, Mequerian-Bedovan Z, Terrier-Lacombe MJ, Robert A, Pondarré C, Leverger G, Devalck C, Rodary C, Delsol G, Hartmann O (1998) CD 30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 92:3591–3598PubMedGoogle Scholar
  6. Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uvttebroeck A, Marky I, Lamant L, Reiter A (2009a) Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL group. J Clin Oncol 27:897–903CrossRefPubMedGoogle Scholar
  7. Brugieres L, Pacquement H, Le Deley MC et al (2009b) Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol 27:5056–5061CrossRefPubMedGoogle Scholar
  8. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A (2005) The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haemtol 131:39–49CrossRefGoogle Scholar
  9. Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, Cieslak A, Minard-Colin V, Rullier A, Moreau A, Baruchel A, Schmitt C, Asnafi V, Bertrand Y, Macintyre E (2012) Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-Cell lymphoblastic lymphoma. J Clin Oncol 30:1966–1973CrossRefPubMedGoogle Scholar
  10. Cheson BD, Fischer RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3067CrossRefPubMedPubMedCentralGoogle Scholar
  11. Eeles RA, O’Brien P, Horwich A, Brada M (1991) Non-Hodgkin’s lymphoma presenting with extradural spinal cord compression: functional outcome and survival. Br J Cancer 63(1):126–129CrossRefPubMedPubMedCentralGoogle Scholar
  12. El-Mahallawy HA, Bahgat N, El-Din HM, Faraq SA, Nouh A, El-Attar I (2004) Hepatitis C virus and its genotypes and helicobacter pylori in pediatric non-Hodgkin’s lymphoma: could there be a possible etiologic role? J Egypt Natl Canc Inst 16(2):114–122PubMedGoogle Scholar
  13. Gupta H, Davidoff AM, Pui CH, Shochat SJ, Sandlund JT (2007) Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. J Pediatr Surg 42(6):998–1001CrossRefPubMedGoogle Scholar
  14. Jenkinson S, Kirkwood AA, Goulden N, Vora A, Linch DC, Gale RE (2016) Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia 30:39–47CrossRefPubMedGoogle Scholar
  15. Kaatsch P. Spix C: German childhood cancer registry – Jahresbericht/Annual report 2015 (1984–2014). Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI), Universitätsmedizin der Johannes Gutenberg-Universität Mainz 2015. http://www.kinderkrebsregister.de/dkkr/ergebnisse/jahresbericht/jahresbericht-2015.html. Zugegriffen am 28.10.2017
  16. Kobos R, Terry W (2015) Advances in therapies for non-Hodgkin lymphoma in children. Hematology Am Soc Hematol Educ Program 2015:522–528PubMedGoogle Scholar
  17. Kontny U, Oschlies I, Woessmann W, Burkhardt B, Lisfeld J, Salzburg J, Janda A, Attarbaschi A, Niggli F, Zimmermann M, Reiter A, Klapper W (2015) Non-anaplastic peripheral T-cell lymphoma in children and adolescents – a retrospective analysis of the NHL-BFM study group. Br J Haematol 168(6):835–844CrossRefPubMedGoogle Scholar
  18. Lamant L, McCarthy K, d’Amore E, Klapper W, Nakagawa A, Fraga M, Maldyk J, Simonitsch-Klupp I, Oschlies I, Delsol G, Mauguen A, Brugiéres L, Le Deley MC (2011) Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol 29:4669–4676CrossRefPubMedGoogle Scholar
  19. Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, Brugiéres L (2010) Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-Vinblastine trial. J Clin Oncol 28:3987–3993CrossRefPubMedGoogle Scholar
  20. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CL, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, His ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS (2012) The genetic landscape of mutations in Burkitt lymphoma. Nature genetics 44:1321–1325CrossRefPubMedPubMedCentralGoogle Scholar
  21. Mansur MB, van Delft FW, Colman SM, Furness CL, Gibson J, Emerenciano M, Kempski H, Clappier E, Cave H, Soulier J, Pombo-de-Oliveira MS, Greaves M, Ford AM (2015) Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia. Br J Haematol 171:574–584CrossRefPubMedPubMedCentralGoogle Scholar
  22. Mauz-Körholz C, Ströter N, Baumann J, Botzen A, Körholz K, Körholz D (2018) Pharmacotherapeutic management of pediatric lymphoma. Paediatr Drugs 20(1):43–57Google Scholar
  23. Minard-Colin V, Brugieres L, Reiter A, Cairo MS, Gross TG, Woessmann W, Burkhardt B, Sandlund JT, Williams D, Pillon M, Horibe K, Auperin A, Le Deley MC, Zimmermann M, Perkins SL, Raphael M, Lamant L, Klapper W, Mussolin L, Poirel HA, Macintyre E, Damm-Welk C, Rosolen A, Patte C (2015) Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol 33(27):2963–2974CrossRefPubMedPubMedCentralGoogle Scholar
  24. Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 98:1283–1291CrossRefPubMedGoogle Scholar
  25. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphome incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276CrossRefPubMedPubMedCentralGoogle Scholar
  26. Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 7:332–339PubMedGoogle Scholar
  27. Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N, Liomba G, Batumba M, Lagos D, Gratix F, Boshoff C, Casabonne D, Carpenter LM, Newton R (2006) Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One 3(6):e2505CrossRefGoogle Scholar
  28. Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, Burkhardt B, Gesk S, Krams M, Reiter A, Siebert A, Klapper W (2010) Pediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the non-Hodgkin’s lymphoma – Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica 95(2):253–259CrossRefPubMedGoogle Scholar
  29. Patte C, Kalifa C, Flamant F, Hartmann O, Brugiéres L, Valteau-Couanet D, Bayle C, Caillaud JM, Lemerle J (1992) Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate on 84 children with non-B-cell (lymphoblastic) lymphoma. Medical and pediatric oncology 20:105–113CrossRefPubMedGoogle Scholar
  30. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MD, FAB/LMB96 International Study Committee (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109:2773–2780PubMedPubMedCentralGoogle Scholar
  31. Pileri SA, Pulford K, Mori S, Mason DY, Sabattini E, Roncador G, Picciolo M, Ceccarelli C, Piccaluga PP, Santini D, Leone O, Stein H, Falini B (1997) Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol 150:1207–1211PubMedPubMedCentralGoogle Scholar
  32. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yasikan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Müller-Weihrich S, Plüss HJ, Zintl F, Henze G, Riehm H (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group trial NHL-BFM 90. Blood 94:3294–3306PubMedGoogle Scholar
  33. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416–421PubMedGoogle Scholar
  34. Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, Reiter A, Cairo MS (2015) Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol 33(18):2112–2118CrossRefPubMedPubMedCentralGoogle Scholar
  35. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fischer RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteve SM, Rickinson AB, Staudt LM (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490:116–120CrossRefPubMedPubMedCentralGoogle Scholar
  36. Swerdlow S, Campo E, Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4. Aufl. WHO, GenevaGoogle Scholar
  37. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A, BFM Group (2005) The impact of methotrexate administration schedule and dose in the treatment of children and adolescents with B cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 105:948–958CrossRefPubMedGoogle Scholar
  38. Woessmann W, Zimmermann M, Lenhard M, Burkhardt B, Rossig C, Kremens B, Lang P, Attarbash A, Mann G, Oschlies I, Klapper W, Reiter A (2011) Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol 29:3065–3071CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für KinderchirurgieUniversitätsklinikum Gießen/MarburgMarburgDeutschland
  2. 2.Abt. für Pädiatrische Hämatologie/OnkologieUniversitätsklinikum Gießen/MarburgGießenDeutschland

Personalised recommendations